



## **Funded Clinical Trial with a Novel Anticancer Agent**

University of Illinois Cancer Care Clinic and  
Comparative Oncology Research Laboratory

**Study Title:** Evaluation of the procaspase-3 activator sulfonamide PAC-1 in dogs with multicentric lymphoma

**Purpose of the study:** Caspase-3 is a cell enzyme that directly leads to cell death. Cancer cells have higher levels of this enzyme compared to normal cells. Sulfonamide PAC-1 is a novel compound which leads to activation of this enzyme, thereby causing cell death in cancer cells and sparing normal cells. The goal of this trial is to determine the pharmacokinetics, safety, and anticancer effects of sulfonamide PAC-1 for dogs diagnosed with multicentric lymphoma. This will be achieved by treating lymphoma-bearing dogs with a 24-hour constant rate infusion of sulfonamide PAC-1 once a week for 4 consecutive weeks.

### **Inclusion Criteria:**

- Dogs with histologically or cytologically confirmed multicentric lymphoma
- Dogs must have a measurable tumor burden
- Dogs must have a favorable performance status
- NO concurrent chemotherapy or radiation therapy. Dogs must be off of all such therapy for 2 weeks prior to study enrollment. Dogs must be off steroids for at least 1 week prior to study enrollment.
- Both newly diagnosed dogs and those with recurrent lymphoma are eligible
- Signed informed owner consent; all treatment options for the pet will be presented and owner must decline all other options
- NO significant co-morbid illness, which includes renal or hepatic failure, history of congestive heart failure or clinical coagulopathy

### **Diagnostics:**

- Diagnostics include: 1) Screening bloodwork and urinalysis, 2) sedation with computed tomography, 3) cytologic evaluation of lymph node before and after therapy, and 4) 6-point pharmacokinetic analysis

### **Treatment:**

- All dogs will be treated with a 24-hour constant rate infusion of sulfonamide PAC-1 weekly for 4 consecutive weeks.

### **Compensation:**

- The study will pay for all diagnostics during the 4 week course of the study. The client will be responsible for some initial diagnostics performed to confirm study eligibility.

**Contact Information:** Please feel free to call Nancy George at (217) 244-7789 to refer a patient or for any additional information. Referring veterinarian and client calls are welcome.